Feb 12 2010
China Cord Blood
Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of
cord blood collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services, today announced that the Securities and
Exchange Commission ("SEC") declared the Company's registration statement
effective on February 9, 2010. The registration statement relates to the
ordinary shares underlying warrants and certain other securities issued in
connection with the initial public offering of Pantheon China Acquisition Corp.
As a result of the effectiveness, holders of public warrants issued and
outstanding may now exercise them and receive ordinary shares upon the payment
of the related exercise price.
SOURCE China Cord Blood Corporation
Study reveals molecular changes in 19 organs due to exercise